Vertex Pharmaceuticals rose Thursday night after the FDA approved its non-opioid painkiller Journavx. It's the first U.S. approval for a new type of painkiller in decades. VRTX stock jumped Friday morning.
The first-in-class drug, also known as suzetrigine, won approval for treating moderate to severe pain in adults. The more-lucrative approval would be for chronic pain.
Vertex stock rose 6% to above 465 on Friday morning, regaining the 200-day line. That could offer an aggressive entry into VRTX stock.
On Dec. 19, VRTX stock dived 11.4% to a 52-week low after suzetrigine failed to best a placebo in treating lower back and hip pain.
Please follow Ed Carson on Threads at @edcarson1971 and X/Twitter at @IBD_ECarson for stock market updates and more.
